Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2002 1
2009 1
2010 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Erythropoietin reaches the pharmacy.
[No authors listed] [No authors listed] Lancet. 1989 Nov 25;2(8674):1252-4. Lancet. 1989. PMID: 2573763 Review. No abstract available.
Impact of illegal trade on the quality of epoetin alfa in Thailand.
Fotiou F, Aravind S, Wang PP, Nerapusee O. Fotiou F, et al. Clin Ther. 2009 Feb;31(2):336-46. doi: 10.1016/j.clinthera.2009.02.014. Clin Ther. 2009. PMID: 19302906
OBJECTIVE: This study assessed the authenticity and quality of epoetin alfa samples in Thailand. METHODS: Samples of epoetin alfa-prefilled syringes were collected from the pharmacies at 2 major hospitals (62 samples), 8 retail pharmacies …
OBJECTIVE: This study assessed the authenticity and quality of epoetin alfa samples in Thailand. METHODS: Samples of epoeti …
Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome.
Jackevicius CA, Co MJ, Warner AL. Jackevicius CA, et al. Int J Pharm Pract. 2015 Jun;23(3):199-204. doi: 10.1111/ijpp.12133. Epub 2014 Jul 2. Int J Pharm Pract. 2015. PMID: 24990704
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines do not specifically address patients with CRAS, creating uncertainty in erythropoietin (EPO) prescribing. We sought to determine predictors of EPO use in patients with CRAS. M …
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines do not specifically address patients with …
Form CMS-2728 data versus erythropoietin claims data: implications for quality of care studies.
Beaubrun AC, Kanda E, Bond TC, McClellan WM. Beaubrun AC, et al. Ren Fail. 2013;35(3):320-6. doi: 10.3109/0886022X.2012.747967. Epub 2012 Dec 11. Ren Fail. 2013. PMID: 23227806
The sensitivity, specificity, and kappa coefficient for the predialysis erythropoietin indicator were 58.0%, 78.4%, and 0.36, respectively. Patients with a predialysis erythropoietin claim were less likely to die compared with patients without a claim (odds ratio = …
The sensitivity, specificity, and kappa coefficient for the predialysis erythropoietin indicator were 58.0%, 78.4%, and 0.36, respect …
Administer but Do Not Dispense: Effect of Change in Medication Handling by Nurses on Outcomes of Home Dialysis Patients.
Ullian ME, Martin CA, Ullian DM. Ullian ME, et al. Am J Med Sci. 2016 Jun;351(6):595-600. doi: 10.1016/j.amjms.2016.02.024. Epub 2016 Feb 23. Am J Med Sci. 2016. PMID: 27238922
BACKGROUND: To come into compliance with South Carolina statute, we changed how nurses handle medications (antibiotics, erythropoietin [EPO], calcitriol and heparin) in our outpatient home dialysis clinic. Nurses continued to administer medications in the clinic but no lon …
BACKGROUND: To come into compliance with South Carolina statute, we changed how nurses handle medications (antibiotics, erythropoietin …
Evaluation of drug-prescribing patterns based on the WHO prescribing indicators at outpatient clinics of five hospitals in Jordan: a cross-sectional study
.
Al-Azayzih A, Al-Azzam SI, Alzoubi KH, Shawaqfeh M, Masadeh MM. Al-Azayzih A, et al. Int J Clin Pharmacol Ther. 2017 May;55(5):425-432. doi: 10.5414/CP202733. Int J Clin Pharmacol Ther. 2017. PMID: 28139971
OBJECTIVE: The main objective of this study was to evaluate the trends and issues related to prescription at outpatient hospital pharmacies in Jordan and to contrast that to the WHO rational medication list and WHO drug use indicators. ...The top three most common prescrib …
OBJECTIVE: The main objective of this study was to evaluate the trends and issues related to prescription at outpatient hospital pharmaci …
How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?
Halim LA, Brinks V, Jiskoot W, Romeijn S, Praditpornsilpa K, Assawamakin A, Schellekens H. Halim LA, et al. Pharm Res. 2014 May;31(5):1210-8. doi: 10.1007/s11095-013-1243-9. Epub 2013 Nov 21. Pharm Res. 2014. PMID: 24258097
PURPOSE: The high prevalence of pure red cell aplasia in Thailand has been associated with the sharp increase in number of recombinant human erythropoietin (rhEPO) copy products, based on a classical generic regulatory pathway, which have entered the market. This study aim …
PURPOSE: The high prevalence of pure red cell aplasia in Thailand has been associated with the sharp increase in number of recombinant human …
Health care resource utilization and the impact of anemia management in patients with chronic kidney disease.
London R, Solis A, Goldberg GA, Wade S, Ryu S. London R, et al. Am J Kidney Dis. 2002 Sep;40(3):539-48. doi: 10.1053/ajkd.2002.34912. Am J Kidney Dis. 2002. PMID: 12200806
RESULTS: Mean age was 66.8 years, 46% were women, 91.2% had claims for facility services, 97.6% had claims for professional services, and 95.7% had claims for outpatient pharmacy, with mean costs per patient of $26,204, $9,623, and $1,503, respectively. ...Comorbid …
RESULTS: Mean age was 66.8 years, 46% were women, 91.2% had claims for facility services, 97.6% had claims for professional services, …
Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P. Lafeuille MH, et al. Consult Pharm. 2010 Aug;25(8):493-500. doi: 10.4140/TCP.n.2010.493. Consult Pharm. 2010. PMID: 20736158
OBJECTIVE: To compare drug-utilization patterns and costs in patients with chronic kidney disease (CKD), not on dialysis, yet receiving epoetin alfa (EPO) or darbepoetin alfa (DARB) in a long-term care setting. DESIGN: A retrospective analysis of pharmacy …
OBJECTIVE: To compare drug-utilization patterns and costs in patients with chronic kidney disease (CKD), not on dialysis, yet receiving e …